当社グループは 3,000 以上の世界的なカンファレンスシリーズ 米国、ヨーロッパ、世界中で毎年イベントが開催されます。 1,000 のより科学的な学会からの支援を受けたアジア および 700 以上の オープン アクセスを発行ジャーナルには 50,000 人以上の著名人が掲載されており、科学者が編集委員として名高い
。オープンアクセスジャーナルはより多くの読者と引用を獲得
700 ジャーナル と 15,000,000 人の読者 各ジャーナルは 25,000 人以上の読者を獲得
Clatte F
The ability to enroll in pancreatic surveillance programs would be made possible by the collection of family history information, which could be a useful tool for identifying individuals who are more likely to develop pancreatic cancer. Weight loss and newly diagnosed diabetes may also be used as an early indicator of pancreatic cancer [1]. Combining family history and the Enriching New-Onset Diabetes for Pancreatic Cancer (ENDPAC) model to identify people who might benefit from pancreatic surveillance is the focus of this study. The ENDPAC model's criteria were combined with questions about family cancer history in a novel questionnaire and digital input tool. The high-risk pancreatic clinic enrolled individuals who met the ENDPAC criteria directly [2 ]. A genetic counselor was recommended to those who met the criteria for a significant family history of cancer. 453 patients completed the questionnaire. 25.8% (117/453) of those had significant risk factors in their families [3]. Five of the 18 people (15.4%) who had previously undergone genetic testing had a pathogenic variant. Out of 117 people who were identified by the questionnaire as having a
significant family history, 34 (29.9%) underwent genetic testing. A pathogenic variant was present in four (11.8 percent) of these patients. Furthermore, through overflow family testing, two kin were found to convey pathogenic variations. From the 453 patients, four (0.9 percent) met the ENDPAC criteria. Two of them had pancreatic cancer, and the other two had signed up for the surveillance program. In conclusion, the ENDPAC model and family history screening can be combined to identify people at high risk for pancreatic cancer and make it easier to refer them to genetic counseling
and high-risk clinics [4 ].